PT  - JOURNAL ARTICLE
AU  - HIROFUMI UTSUMI
AU  - YOSHITAKA HONMA
AU  - KENGO NAGASHIMA
AU  - SATORU IWASA
AU  - ATSUO TAKASHIMA
AU  - KEN KATO
AU  - TETSUYA HAMAGUCHI
AU  - YASUHIDE YAMADA
AU  - YASUHIRO SHIMADA
AU  - YOJI KISHI
AU  - SATOSHI NARA
AU  - MINORU ESAKI
AU  - KAZUAKI SHIMADA
TI  - Bevacizumab and Postoperative Wound Complications in Patients with Liver Metastases of Colorectal Cancer
DP  - 2015 Apr 01
TA  - Anticancer Research
PG  - 2255--2261
VI  - 35
IP  - 4
4099  - http://ar.iiarjournals.org/content/35/4/2255.short
4100  - http://ar.iiarjournals.org/content/35/4/2255.full
SO  - Anticancer Res2015 Apr 01; 35
AB  - Aim: The present study investigated whether bevacizumab (BV) is associated with postoperative wound complications (PWCs). Patients and Methods: We retrospectively analyzed patients undergoing surgery for liver metastases of colorectal cancer at our Institution. Patients were divided into 3 groups according to the preoperative treatment: che mo therapy with BV (group A), chemotherapy without BV (group B) and no chemotherapy (group C). Results: Between February 2003 and September 2012, 297 patients underwent 373 surgeries. Groups A, B and C consisted of 23, 62 and 288 patients, respectively. PWCs occurred in 29 patients (7.8%). In multivariate analysis, there were no differences in PWCs among the groups (C vs. B:P=0.739; C vs. A: P=0.110). Conversely, lower serum albumin levels (<3.5g/dl vs. ≥3.5g/dl: p=0.030) and synchronous colorectal resection (no vs. yes; p<0.001) remained significant risk factors of developing PWCs. Conclusion: Chemotherapy with or without BV did not influence the risk of PWCs.